Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...
Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.
Had the Dateline NBC vet not gone public with her decision to vacate her Today spot, Hoda Kotb might have been the one ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Gross dollar volume rose 9% in the second quarter, while purchase volume was up 10% from one year ago. Mastercard's resilient business model hasn't just led to immense financial strength -- it's also ...
Filming is underway on Netflix's adaptation of Alice Feeney's His & Hers starring Tessa Thompson and Jon Bernthal.
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.
The container ship Sky Light caused chaos while docking at a port in Constanța, Romania, on September 19. While attempting to ...
Fox 4's Austin Schargorodski reports on a Cape Coral woman arrested for trying to sell a boat that wasn’t hers, using forged ...
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback